Compare AXR & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXR | MSLE |
|---|---|---|
| Founded | 1961 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 154.6M |
| IPO Year | 2010 | 2007 |
| Metric | AXR | MSLE |
|---|---|---|
| Price | $22.51 | $9.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 44.8K |
| Earning Date | 03-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $12,831,000.00 | N/A |
| Revenue This Year | $10.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $5.44 |
| 52 Week High | $29.01 | $13.39 |
| Indicator | AXR | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 58.10 |
| Support Level | $21.92 | $9.10 |
| Resistance Level | $23.52 | $10.57 |
| Average True Range (ATR) | 0.80 | 0.51 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 47.36 | 48.88 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.